KEYNOTE-604: Phase 3 Randomized, Double-Blind Trial of Pembrolizumab/Placebo plus Etoposide/Platinum for Extensive Stage-SCLC

被引：6

作者：

Rudin, C. ^{[1
]}

Shen, L. ^{[2
]}

Pietanza, M. C. ^{[2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Merck & Co Inc, Kenilworth, NJ USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

KEYNOTE-604; pembrolizumab; small-cell lung cancer;

D O I：

10.1016/j.jtho.2017.11.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.04-007

引用

页码：S2400 / S2400

页数：1

共 50 条

[1] Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC
Rudin, Charles M.
Ryun Kim, Hye
Navarro, Alejandro
Gottfried, Maya
Peters, Solange
Csoszi, Tibor
Kaur Cheema, Parneet
Rodriguez-Abreu, Delvys
Wollner, Mira
Chih-Hsin Yang, James
Mazieres, Julien
Kato, Terufumi
Peter Kalemkerian, Gregory
Dettman, Elisha
Edmondson, Mackenzie
Vajdi, Amir
Loboda, Andrey
Edmond El-Osta, Hazem
Zhao, Bin
Awad, Mark M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Rudin, Charles M.
Awad, Mark M.
Navarro, Alejandro
Gottfried, Maya
Peters, Solange
Csoszi, Tibor
Cheema, Parneet K.
Rodriguez-Abreu, Delvys
Wollner, Mirjana
Yang, James Chih-Hsin
Mazieres, Julien
Orlandi, Francisco J.
Luft, Alexander
Gumus, Mahmut
Kato, Terufumi
Kalemkerian, Gregory P.
Luo, Yiwen
Ebiana, Victoria
Pietanza, M. Catherine
Kim, Hye Ryun
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (21) : 2369 - +
[3] KEYNOTE-604: Phase 3 trial of pembrolizumab plus etoposide/platinum (EP) for first-line treatment of extensive stage small-cell lung cancer (ES-SCLC)
Rudin, C. M.
Shen, L.
Pietanza, M. C.
ANNALS OF ONCOLOGY, 2017, 28
[4] KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).
Rudin, Charles M.
Awad, Mark M.
Navarro, Alejandro
Gottfried, Maya
Peters, Solange
Csoszi, Tibor
Cheema, Parneet Kaur
Rodriguez-Abreu, Delvys
Wollner, Mira
Czyzewicz, Grzegorz
Yang, James Chih-Hsin
Mazieres, Julien
Orlandi, Francisco J.
Luft, Alexander
Gumus, Mahmut
Kato, Terufumi
Kalemkerian, Gregory Peter
Luo, Yiwen
Pietanza, Maria Catherine
Kim, Hye Ryun
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[5] Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
Cheng, Ying
Fan, Yun
Zhao, Yanqiu
Huang, Dingzhi
Li, Xingya
Zhang, Peng
Kang, Mafei
Yang, Nong
Zhong, Diansheng
Wang, Zhen
Yu, Yan
Zhang, Yu
Zhao, Jun
Qin, Tai
Chen, Chenqi
Leaw, Shiangjiin
Zheng, Wenjuan
Song, Yong
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : 1073 - 1085
[6] Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive SCLC
Kim, Hye Ryun
Awad, Mark M.
Navarro, Alejandro
Gottfried, Maya
Peters, Solange
Csoszi, Tibor
Cheema, Parneet K.
Rodriguez-Abreu, Delvys
Wollner, Mirjana
Yang, James Chih-Hsin
Mazieres, Julien
Orlandi, Francisco J.
Luft, Alexander
Gumus, Mahmut
Kato, Terufumi
Kalemkerian, Gregory P.
Luo, Yiwen
Santorelli, Melissa L.
Pietanza, M. Catherine
Rudin, Charles M.
JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (11):
[7] KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC
Wakelee, Heather A.
Liberman, Moishe
Kato, Terufumi
Tsuboi, Masahiro
Lee, Se-Hoon
He, Jie
Gao, Shugeng
Chen, Ke-Neng
Dooms, Christophe Alfons
Majem, Margarita
Eigendorff, Ekkehard
Martinengo, Gaston Lucas
Bylicki, Olivier
Rodriguez-Abreu, Delvys
Chaft, Jamie E.
Novello, Silvia
Yang, Jing
Keller, Steven M.
Samkari, Ayman
Spicer, Jonathan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA100 - LBA100
[8] KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
Wakelee, Heather A.
Liberman, Moishe
Kato, Terufumi
Tsuboi, Masahiro
Lee, Se-Hoon
He, Jie
Gao, Shugeng
Chen, Ke-Neng
Dooms, Christophe Alfons
Majem, Margarita
Eigendorff, Ekkehard
Martinengo, Gaston Lucas
Bylicki, Olivier
Rodriguez-Abreu, Delvys
Chaft, Jamie E.
Novello, Silvia
Yang, Jing
Keller, Steven M.
Samkari, Ayman
Spicer, Jonathan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[9] First-Line Pembrolizumab or Placebo Combined with Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results
Rudin, C. M.
Kim, H. R.
Navarro, A.
Gottfried, M.
Peters, S.
Csoszi, T.
Cheema, P. K.
Rodriguez-Abreu, D.
Wollner, M.
Czyzewicz, G.
Yang, J. C. -H.
Mazieres, J.
Orlandi, F. J.
Luft, A.
Gumus, M.
Kato, T.
Kalemkerian, G. P.
Fu, W.
Zhao, B.
El-Osta, H.
Awad, M. M.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S33 - S34
[10] Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC
Kim, H. R.
Awad, M. M.
Navarro, A.
Gottfried, M.
Peters, S.
Csoszi, T.
Cheema, P. K.
Rodriguez-Abreu, D.
Wollner, M.
Yang, J. C-H.
Mazieres, J.
Orlandi, F. J.
Luft, A.
Gumus, M.
Kato, T.
Kalemkerian, G. P.
Luo, Y.
Santorelli, M. L.
Pietanza, M. C.
Rudin, C. M.
ANNALS OF ONCOLOGY, 2020, 31 : S1033 - S1034

← 1 2 3 4 5 →